ITCI Live signals | Maximize Profits with Getagraph.com

SELL 3500 min ago

@ $66.73

Issued: 31 May 2024 @ 14:37

Return: 0.76%

Previous signal: May 31 - 13:49

Previous signal: Buy

Return: 0.89 %

Live Chart Being Loaded With Signals

Commentary (31 May 2024 @ 16:00):

Stats
Today's Volume	943 651
Average Volume	952 690
Market Cap	7.10B
EPS	$0 ( 2024-05-02 )
Next earnings date	( $-0.190 ) 2024-08-01
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-57.97
ATR14	$1.181 (1.76%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-24	Mates Sharon	Buy	11 382	Common Stock
2024-04-24	Mates Sharon	Buy	8 638	Common Stock
2024-04-24	Mates Sharon	Sell	11 382	Stock Option (right to buy)
2024-04-24	Mates Sharon	Sell	8 638	Stock Option (right to buy)
2024-03-31	Van Nostrand Robert L	Buy	79	Common Stock

INSIDER POWER
1.81
Last 100 transactions
Buy: 523 032 \| Sell: 503 157

Volume Correlation

Long: 0.93 (very strong)

Short: -0.80 (moderate negative)

Signal:(55) Neutral

Intra-Cellular Therapies Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Intra-Cellular Therapies Correlation - Currency/Commodity

0.89
( strong )

0.81
( strong )

-0.68
( moderate negative )

0.84
( strong )

-0.41
( neutral )

Intra-Cellular Therapies Financials

Annual	2023
Revenue:	$462.18M
Gross Profit:	$428.43M (92.70 %)
EPS:	$-1.460

FY	2023
Revenue:	$462.18M
Gross Profit:	$428.43M (92.70 %)
EPS:	$-1.460

FY	2022
Revenue:	$249.13M
Gross Profit:	$228.69M (91.79 %)
EPS:	$-2.72

FY	2021
Revenue:	$83.80M
Gross Profit:	$75.77M (90.41 %)
EPS:	$-3.50

Financial Reports:

No articles found.

Intra-Cellular Therapies Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Intra-Cellular Therapies

Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in developing lumateperone, which is in Phase III clinical trial for the treatment of bipolar depression, as well as to treat autism spectrum disorder; and in additional neuropsychiatric indications, such as sleep disorders associated with neuropsychiatric and neurological disorders. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease and heart failure; ITI-1284-ODT-SL for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression and anxiety. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.